[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.140.252. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Views 457
Citations 0
Correction
February 8, 2012

Clarification of Conflict of Interest Disclosures in: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes

JAMA. 2012;307(6):563. doi:10.1001/jama.2012.113

Clarification of Conflict of Interest Disclosures: In the Editorial entitled “Hospitalizations for Heart Failure in the United States—A Sign of Hope,” published in the October 19, 2011, issue of JAMA (2011;306[15]:1705-1706), and in the Commentary entitled “A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes,” published in the April 27, 2011, issue of JAMA (2011;305[16]:1702-1703), the conflict of interest disclosure information for Dr Braunwald should have read as follows: Dr Braunwald reported receiving research support from Merck, AstraZeneca, Johnson & Johnson, Beckman Coulter, Eli Lilly, Roche Diagnostics, sanofi-aventis, Daiichi Sankyo, GlaxoSmithKline, Bristol-Myers Squibb, and Pfizer as well as participating in symposia, advisory board meetings, and/or consultancies for the following companies: Eli Lilly, Merck, Genzyme, Amorcyte, CVRx (no compensation), The Medicines Company, CV Therapeutics, Daiichi Sankyo, MC Communications, Ortho McNeil, Ikaria, Menarini International, CardioRentis, and sanofi-aventis. Also in the Commentary, the conflict of interest disclosure for Dr Gheorghiade should have read as follows: Dr Gheorghiade reported that he received consulting fees from Bayer, Novartis, Sigma Tau, Johnson & Johnson, Takeda, Otsuka, and Medtronic. These 2 articles were corrected online. A letter regarding the differences in Dr Braunwald's conflict of interest disclosures appears in this issue.

×